Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity - PubMed (original) (raw)
. 1996 Dec 15;56(24):5557-62.
Affiliations
- PMID: 8971152
Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity
I Kinoshita et al. Cancer Res. 1996.
Abstract
p16INK4 protein (p16) and retinoblastoma protein (pRB), like p53 protein, are important tumor suppressors that regulate the cell cycle. We immunohistochemically examined fresh-frozen specimens of 114 resected non-small cell lung cancers (NSCLCs) for loss of p16 and pRB expression, together with aberrant accumulation of p53 protein and the proliferative activity determined by the Ki-67 index. Three pRB-positive tumors were uninterpretable for p16 status. Of the remaining 111 tumors, 30 (27%) lacked p16 expression, and 10 (9%) lost pRB expression. No tumors showed coincident loss of both proteins, supporting the hypothesis that they function in a single pathway. Of 25 tumors, including 4 p16-negative tumors, examined by Southern blot analysis, only 2 p16-negative tumors were considered to have reduced gene dosage consistent with possible homozygous deletion of the CDKN2 gene encoding p16, suggesting that immunohistochemistry is a sensitive and suitable method to screen for p16 alteration. Loss of p16 expression did not correlate with any clinical factors or p53 status, whereas loss of pRB expression correlated with heavy smoking (P = 0.03 by Fisher's exact test and P = 0.01 by the multivariate logistic regression analysis). Proliferative activity was considerably higher in p53-positive tumors than in p53-negative tumors (P < 0.001). Loss of p16 or pRB expression was associated with a further increase in proliferative activity in the p53-positive tumors (P = 0.009) but not with proliferative activity in the p53-negative tumors. These results suggest that alteration of the p16/pRB pathway is relatively frequently involved in the development and progression of NSCLCs and that its effect on the proliferative activity is potentially synergistic with altered p53 protein.
Similar articles
- Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
Hirabayashi H, Ohta M, Tanaka H, Sakaguchi M, Fujii Y, Miyoshi S, Matsuda H. Hirabayashi H, et al. J Surg Oncol. 2002 Dec;81(4):177-84; discussion 184. doi: 10.1002/jso.10176. J Surg Oncol. 2002. PMID: 12451621 - p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. Shariat SF, et al. J Clin Oncol. 2004 Mar 15;22(6):1014-24. doi: 10.1200/JCO.2004.03.118. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981102 - [Prognostic importance of altered expression of cell cycle regulators in lung cancer].
Akita H. Akita H. Nihon Rinsho. 2002 May;60 Suppl 5:267-71. Nihon Rinsho. 2002. PMID: 12101670 Review. Japanese. No abstract available. - [Proliferative activity and defective replication in breast cancer].
Kreipe H, Zeidler R, Kneitz H, Feist H. Kreipe H, et al. Verh Dtsch Ges Pathol. 1994;78:36-7. Verh Dtsch Ges Pathol. 1994. PMID: 7534009 Review. German.
Cited by
- Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C. Gorgoulis VG, et al. Mol Med. 1998 Dec;4(12):807-22. Mol Med. 1998. PMID: 9990866 Free PMC article. - Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers.
Hommura F, Dosaka-Akita H, Kinoshita I, Mishina T, Hiroumi H, Ogura S, Katoh H, Kawakami Y. Hommura F, et al. Br J Cancer. 1999 Oct;81(4):696-701. doi: 10.1038/sj.bjc.6690750. Br J Cancer. 1999. PMID: 10574258 Free PMC article. - Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome.
Mishina T, Dosaka-Akita H, Kinoshita I, Hommura F, Morikawa T, Katoh H, Kawakami Y. Mishina T, et al. Br J Cancer. 1999 Jun;80(8):1289-95. doi: 10.1038/sj.bjc.6990500. Br J Cancer. 1999. PMID: 10376986 Free PMC article. - The implication of background anthracosis in the development and progression of pulmonary adenocarcinoma.
Wang D, Minami Y, Shu Y, Konno S, Iijima T, Morishita Y, Noguchi M. Wang D, et al. Cancer Sci. 2003 Aug;94(8):707-11. doi: 10.1111/j.1349-7006.2003.tb01506.x. Cancer Sci. 2003. PMID: 12901796 Free PMC article. - Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions.
Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Sano T, et al. Am J Pathol. 1998 Dec;153(6):1741-8. doi: 10.1016/S0002-9440(10)65689-1. Am J Pathol. 1998. PMID: 9846965 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous